Nov. 14 at 5:32 PM
$HUMA Risk reward to buy shares at this price is assymetrical! This is currently one of the best times to buy this stock. Any deal (DOD contract or something else) that would calm investors that no other dilution is necessary will let price explode to
$2-3 range. Trauma sales will pick up slowly and steadily while more and more surgeons, hospitals and insurances will get to know the product. If in 18 months time Dyalisis will get approved, stock price will explode to
$5-6. HAV for dyalisis will gain market share much faster since A) Fresenius is the biggest player in that space and will push HAV sales B) the medical world already knows Symvess. Company at that time has enough money to finalize PAD (huge market and not far away), Cagb plus pancreas. At this price risk reward clearly says buy to me!
